EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN

〰️

EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN 〰️

Most of the current tumor-targeted antibodies only serve a subset of patients and a subset of cancers. Many of them also unintentionally target healthy tissues, causing severe side effects.

“We aim to become the leading provider of truly tumor-specific mAb-based therapies. Our solution is for all cancer patients, across all cancer types, without targeting healthy cells.

We will pioneer the future of anti-cancer therapy! ”

OUR MISSION

The iDEAL discovery of high affinity combotope antibodies

Sugars (glycans) play a crucial role in modifying many essential proteins in our bodies, including those found on the surfaces of cancer cells. In most cancers, these sugar structures are shortened compared to healthy cells, offering a unique opportunity to differentiate between cancerous and normal cells.

Combotope Therapeutics proprietary mAb discovery platform is designed to target cancer cells without impacting healthy cells. Our integrated Design Antibody Libraries (iDEAL), combines glycan and peptide-focused scFv technology, providing antibodies with pM affinities that specifically target the tumor form of a particular protein on cancer cells while leaving healthy cells untouched. Our scFv sequences are compatible with numerous therapeutic modalities for effective cancer treatment.

We offer an attractive partnership business model.

We identify, develop, and license proprietary scFv sequences that specifically target cancer proteins with aberrant O-glycosylation.

Through strategic partnerships, we advance the development and commercialization of pioneering scFv-based off-the-shelf and personalized anti-cancer therapies.

Our combined tumor glycan-protein targeting strategy allows revisiting current targets, previously intractable and abandoned targets, as well as new targets discovered by partners or from new academic discoveries.

EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN, LAG-3, Fn14, S1PR3, ..and many more

Our proprietary iDEAL discovery platform allows identification of unique, patentable scFv sequences dictated by aberrantly glycosylated protein targets. This provides scFv fragments with superior benefits for our partners:

  • Novel class of mAbs

  • Cancer selective

  • Target specific

  • High affinity

  • No targeting of healthy tissue.

  • Untouched IP space​

Our scFv antibody format provides customized Plug'N'Play solutions for our partners and enables the development of pioneering anti-cancer treatment modalities.

  • IgG mAb​

  • ADC​

  • CAR​-T

  • BiTE​’s

  • Immunocytokine

  • Radiolabeled

  • And more

“The potential of antibody-based therapies targeting aberrantly glycosylated cancer-specific proteins might provide a safer alternative than targeting shared, overexpressed tumor antigens”
— KOL
“By tapping into a wealth of addressable therapeutic targets, we challenge the boundaries of what’s possible in cancer treatment for any patient”
— Søren Jakobsen, founder, COO

We offer an attractive partnership business model that advances win-win relationships.

  • Upfront, and milestone payments tied to development and regulatory achievements

  • Minimum royalties and royalties based on product sales.

“We can do things our partners cannot, our partners can do things we cannot, together we do great things”
— Ola Blixt, Inventor, founder, CEO

Management

  • Dr. Klas Ola Blixt

    CO-FOUNDER, INVENTOR, & CEO

    Ola is the inventor of the Combotope concept and possesses a profound understanding of aberrant glycosylation, enabling the generation of cancer-specific and cancer-selective antibodies. With over 20 years of experience in both basic and applied research across fields such as chemical biology, glycoscience, monoclonal antibodies, and biomarkers, Ola has produced several highly cited publications (h=50) and holds numerous patents. Moreover, Ola brings more than 15 years of management and leadership experience to the table.

  • Dr. Søren Nyboe Jakobsen

    CO-FOUNDER, COO

    Søren is an inventor/co-inventor of patents related to molecular display and molecular selection techniques, as well as technologies for the detection and characterization of B-, and T cells. Most recently, Søren was the founder and CEO of Tetramer Shop (acquired by 10x Genomics). He has previously created foundational IP, platforms, products, and services at notable companies such as Novo Nordisk, Nuevolution (acquired by Amgen), Immudex, PokeACell, and 10x Genomics. Søren has extensive management and leadership experience.

Science Advisors

  • Professor Andreas H. Laustsen-Kiel​

    Co-founder, Center for Antibody Technologies, DTU Bioengineering​

  • Professor Richard Cummings​

    Tumor glycobiology, Harvard Medical School Department of Surgery

  • Professor Ramon Hurtado Guerrero

    Co-inventor​, Structural biology, University of Zaragoza

  • Professor Nico Callewaert

    Director, VIB Center for Medical Biotechnology, Biochemistry and Biotechnology, UGent

Book a tee time with us, and we'll provide you with further details on glycosylation, our company, and the potential for collaboration.

Messi is our Chief Bonding Officer (CBO). He's been an amazing team member, but we're opening the leash to new applicants at Combotope. Don't worry, Messi's totally cool with it – he's all excited about our animal-free solutions. So, if you're ready let's chat!

Combotope Therapeutics ApS

Diplomvej 381

DK-2800 Kongens Lyngby

Denmark

Contact:

olablixt@combotope.com

Company registration (CVR) no. 44308266